Invesco Preferred ETF (PGX) Stock Price Today
Aura AI Summary
Key Stats
- $3.54BMarket Cap
- 8,680,372Volume
- -Sector
- $11.5152W High
- $9.8552W Low
- 98 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 100% Sell | 0% BuyTrading Activity
Track Invesco Preferred ETF (PGX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Invesco Preferred ETF has traded between a low of $9.85 and a high of $11.51, highlighting its annual price range. Buy and sell Invesco Preferred ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Most Recent News
3E Network faces Nasdaq delisting over low share price, plans hearing to appeal and regain compliance.
3E Network Technology Group Limited received a notice from Nasdaq that its Class A shares will be delisted due to the share price falling below $1.00 for 30 consecutive business days. The company is not eligible for a compliance period because of a r...
Atlas Copco expands US manufacturing with new facilities in New York and South Carolina
Atlas Copco Group completed Expansion Week in the US, unveiling three major manufacturing expansions in New York and South Carolina. The new facilities will increase production of oil-free compressors, dry vacuum pumps, and gas and process equipment,...
FDA grants accelerated approval to INOVIO's VOCERYQ, a nonsurgical DNA therapy for adults with RRP, launching in early 2027.
INOVIO received accelerated FDA approval for VOCERYQ, a DNA-based immunotherapy that reduces surgery frequency in adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV-6 and HPV-11. VOCERYQ, the first FDA-approved DNA m...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.